Acquisition backstory FARAPULSE is now part of Boston Scientific, highlighting a successful exit and ongoing integration. This presents opportunities to pursue cross-sell of complementary electrophysiology solutions, leveraging Boston Scientific channels and distributor networks for expanded market access.

PFA leadership The company developed pulsed field ablation (PFA) for atrial fibrillation, a non-thermal ablation approach. This positions a potential sales angle to clinics seeking innovative, less thermal ablation therapies and differentiation from traditional RF/oasis technologies.

SMB to mid-market focus With a small team and a founder-led origin, there may be lean sales cycles and direct engagement opportunities at hospitals and clinics that are evaluating next-generation EP technologies for strategic growth without large enterprise procurement barriers.

Growth signals Recent news indicates continued visibility of FARAPULSE through press coverage of acquisitions and product development. This momentum can be leveraged to position new product updates, clinical data, and case studies to drive urgency in procurement decisions.

Competitive positioning In a field with major players like Biotronik, Medtronic, Abbott, and Boston Scientific, emphasize the unique PFA technology and potential clinical and procedural benefits to differentiate in bids and RFPs, while aligning with Boston Scientific’s broader EP portfolio.